The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 19, 2024
Filed:
Dec. 09, 2021
Applicant:
Acceleron Pharma Inc., Cambridge, MA (US);
Inventors:
Asya Grinberg, Lexington, MA (US);
John Knopf, Carlisle, MA (US);
Robert S. Pearsall, North Reading, MA (US);
Ravindra Kumar, Acton, MA (US);
Jasbir Seehra, Lexington, MA (US);
Assignee:
ACCELERON PHARMA INC., Rahway, NJ (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 14/71 (2006.01); C07K 16/18 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 14/71 (2013.01); C07K 16/18 (2013.01); C07K 2317/52 (2013.01); C07K 2319/30 (2013.01);
Abstract
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.